<DOC>
	<DOCNO>NCT01128855</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics , safety tolerability single subcutaneous administration GSK2402968 non-ambulant boy Duchenne muscular dystrophy</brief_summary>
	<brief_title>A Double-blind , Escalating Dose , Randomized , Placebo-controlled Study Assessing PK , Safety , Tolerability Non-ambulant DMD Subjects</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Duchenne muscular dystrophy result mutation DMD gene , confirm sponsor approve DNA diagnostic technique cover DMD gene exon , include limited MLPA ( Multiplex Ligationdependent Probe Amplification ) , CGH ( Comparative Genomic Hybridisation ) , SCAIP ( Single Condition Amplification/Internal Primer ) HRMCA ( HighResolution Melting Curve Analysis ) , correctable treatment GSK2402968 . Age 9 year old great Screening ; Male ; Nonambulant ( least 1 year wheelchair ) within last 4 year ; Life expectancy least three year ; Willingness ability comply protocol requirement procedure ; QTc &lt; 450msec ( base single average QTc value triplicate ECGs obtain brief recording period ) . Note : QTc may either QTcB QTcF , machine read manual overread ; Subjects must willing use adequate contraception ( condoms abstinence ) , Screening least 5 month last dose study drug ; Informed assent and/or consent write sign subject and/or parent ( ) /legal guardian ( accord local regulation ) . Any additional mutation ( additional miss exon DMD ) treat GSK2402968 ; Current history liver renal disease ; Acute illness within 4 week anticipate administration study medication , may interfere study assessment ; Use anticoagulant , antithrombotics antiplatelet agent , previous treatment investigational drug , idebenone form Coenzyme Q10 , within 6 month first administration study medication ; Start glucocorticosteroids within 6 month nonstable use glucocorticosteroids within 3 month anticipate first administration study medication ; Positive hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody test ( HCV ) , human immunodeficiency virus ( HIV ) test Screening ; Symptomatic cardiomyopathy ; Use alcohol Screening 1 month Followup visit ; Any Child Care .</criteria>
	<gender>Male</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Duchenne</keyword>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>968</keyword>
</DOC>